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Acetylsalicylic Acid Gastro-resistant
Capsules
M. E. Pina* and A. T. Sousa
Laboratory of Galenic and Pharmaceutical Technology, Faculty of
Pharmacy, University of Coimbra, 3000 Coimbra, Portugal
ABSTRACT
Enteric coating of hard gelatin capsules by application of hydroalcoholic solutions
of formaldehyde was studied and developed in accordance with previous publica-
tions. It is possible to affirm that this coating constitutes a simple, stable, repro-
ducible, and inexpensive method, being a valid alternative to those which have
been proposed. The aim of the present investigation is the preparation of acetyl-
salicylic acid gelatin capsules with good conditions of gastro-resistance and
enteros solubility.
Key Words: Acetylsalicylic acid; Disintegration; Drug release; Formaldehyde;
Gastro-resistant capsules; Stability
INTRODUCTION
Acetylsalicylic acid is one of the most useful
drugs because of its analgesic, antipyretic, anti-
inflammatory, and inhibitory effects on platelet aggre-
gation. However, the use of this drug can cause com-
plications such as gastro-irritation, ulcers, and gastric
hemorrhage. These problems can be diminished by
an enteric coating that eliminates dissolution in the
stomach, thus protecting the gastric mucosa from
the erosive action of acetylsalicylic acid (1,2).
The high enteric absorption of acetylsalicylic acid
can seem contradictory if only the pH partition
theory is considered (3). Several studies demonstrate
that apparently ionized drugs in totality can be
absorbed, because a pH value of 5.3 is present at
the intestinal epithellium, which defines the dissocia-
tion degree of the drug that is absorbed. On the
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other hand it was proved that, when a drug has
high permeability through the intestinal mucosa, its
absorption rate is related to the circulation rate,
which is higher than in the gastric mucosa. These
two facts, associated with the greater intestinal
surface, explain the high enteric absorption of the
acetylsalicylic acid (4,5). Paying attention to pre-
vious considerations, it is possible to affirm that this
drug must be submitted to an enteric coating.
The basis of the described enteric procedure is the
crosslinking of gelatin with formaldehyde. In pre-
vious work, this reaction was monitored by Fourier
transform-infrared (FT-IR) spectroscopy. Principal
component regression analysis of the spectra
recorded at different times was carried out in order
to ensure that spectral vibration was more objec-
tively analyzed. The results demonstrate that the
reaction is initialized by the lysine–methylol for-
mation and is subsequently followed by arginine–
methylol, which in turn reacts with lysine–methylol
to originate arginine–lysine crosslinks (6).
The main purpose of this study is to obtain
stable gastro-resistant acetylsalicylic gelatin cap-
sules, taking into consideration that not more than
10% of the drug should be released from capsules
on in vitro dissolution in simulated gastric fluid
(2 hr), and that in a subsequent test using simulated
intestinal fluid (0.75 hr), not less than 75% of the
active ingredient should be dissolved (7,8).
MATERIALS AND METHODS
Materials
The materials employed were as follows: 00, 0
hard gelatin capsules (colorless; Capsugel, Colmar,
France), 0 hard gelatin capsules (not transparent;
Capsugel). Acetylsalicylic acid (125–315 mm;
125–400 mm; Bayer, Coimbra, Portugal). Simulated
gastric and intestinal fluids [preparation carried out
in accordance with USP XXII (8)]. Ethyl alcohol
75% (v/v), formaldehyde (36.6% w/w), and sodium
hydroxide, all of analytical grade (Merck, Lisboa,
Portugal).
Formulations
Preliminary tests were carried out to define the
acetylsalicylic acid granulometry and the conditions
of formaldehyde treatment, which allowed us to
obtain the previously established properties.
Relative to the drug release in simulated gastric
fluid, the best results were achieved when the
capsules were filled with acetylsalicylic acid (125–
315 mm) but the drug showed a ‘‘clumping effect,’’
with a low drug release in simulated intestinal fluid;
this fact was observed by other researchers (9,10).
So, the capsules were filled manually with acetyl-
salicylic acid (125–400 mm) and sealed in accordance
with previous work (11–13).
Coating Procedure
The different capsules were subjected to the fol-
lowing regime:
. formaldehyde concentration 3% (prepared
from formaldehyde 36.6% w/w 8.2 g, ethyl
alcohol 95% v/v 71.1 g, and water 20.7 g);
. alc. degree of formaldehyde solution 75% (v/v);
. immersion time in formaldehyde solution
15min;
. first drying at 37C for 30min;
. washing with alcohol 75% (v/v) for 15min;
. second drying at 37C for 16 hr
or:
. second drying at 37C for 30minþ15.5hr at
ambient temperature.
Characteristics of the Formulations
The appearance of capsule shells and contents
was observed. The weight uniformity was deter-
mined in accordance with Farmacopeia Portuguesa
V (FPV) (14).
Capsule Size
The studies were carried out with acetylsalicylic
acid capsules (00, 665mg) and (0, 476mg); the
referred amounts allowed their filling up.
Quantification of Free and Residual
Formaldehyde
The values of free and residual formaldehyde
were respectively determined by high-performance
liquid chromatography (HPLC) measurements
(12,15).




































Quantification of Active Substance
Drug concentrations in simulated gastric and
intestinal fluids were determined spectrophoto-
metrically from the formulations at 303 nm (16,17).
Disintegration Testing
The disintegration performance of capsules was
evaluated as described previously (12).
Dissolution Testing
The different capsules (attached with a few
turns of wire helix that would otherwise float)
were subjected to dissolution testing using a disso-
lution apparatus with rotative paddle (Hanson
Research, Northbridge, CA, USA) for 2 hr in
simulated gastric fluid maintained at 37C and at
speed 50 rpm. After this time the intact capsules
were first rinsed in water and immediately
immersed in simulated intestinal fluid for 75min.
Filtered samples were withdrawn and analyzed
spectrophotometrically, at regular intervals.
Stability Studies
During the storage, the gastro-resistant dosage
forms are subjected to physical and chemical altera-
tions than can modify the lioavailabity and bio-
availability of drugs (18,19). Paying attention to
these considerations, residual formaldehyde, disinte-
gration, and dissolution tests were determined on
capsules, immediately after coating and at the end
of 1, 2, 3, and 6 months of holding the capsules
packed in plastic bottles, well stoppered, at 37C
and a relative humidity of 20–25%, or at ambient
temperature and a relative humidity of 40–50%.
RESULTS AND DISCUSSION
Characteristics of the Formulations
During our study the capsules presented no phy-
sical or content modifications. Weight uniformity
was in accordance with the limits of FPV (14).
Determination of ‘‘Free’’ and Residual
Formaldehyde
The results from Table 1 demonstrate that
higher values are represented by colorless capsules
(00), validating the previous results (12). The color-
less and not transparent capsules (0) showed iden-
tical results, which indicates that the presence
of titanium dioxide does not affect the coating
procedure.
On the other hand Tables 2 and 3 indicate that the
residual formaldehyde changed with the inverse ratio
of the ageing time, but from 3 months of storage
onwards stabilization is evident. These results are in
accordance with a previous study (12). The residual
formaldehyde concentration does not constitute any
difficulty for capsule administration (20).
Table 2
Residual Formaldehyde After Second Drying at 37C
Residual Formaldehydea (mg/capsule)
Batch After Coating 1 Month 3 Months 6 Months
Colorless 00 0.4110.015 0.1020.007 0.0770.007 0.0660.002
Colorless 0 0.3120.010 0.0780.001 0.0480.005 0.0410.002
Not transparent 0 0.3100.020 0.0750.004 0.0410.003 0.0390.004
aMean values of five experimentsconfidence interval (95%).
Table 1






Colorless 00 0.6620.041 0.033 4.94
Colorless 0 0.4380.027 0.022 4.95
Not transparent 0 0.4560.007 0.005 1.20
aMean values of five experimentsconfidence interval (95%).
bStandard deviation.




































Disintegration Time of Capsules
The disintegration time of uncoated capsules was
2min in simulated gastric fluid. Tables 4 and 5
show that the disintegration performance was con-
stant during storage for all capsules.
Dissolution Testing
The results related to the dissolution profiles of
the studied formulations are shown in Figs. 1–7.
The described results allow us to conclude the fol-
lowing: the studied coating makes it possible to
obtain capsules with a good gastro-resistance, pres-
enting an acetylsalicylic acid release in simulated
gastric fluid lower than 5% and in simulated intest-
inal fluid greater than 85% at the end of 45min for
all kinds of capsules tested. The drying procedure,
size, or gelatin composition did not influence the
obtained results.
Stability Studies
Analyzing the identical results of residual formal-
dehyde, disintegration, and dissolution times for all
tested capsules after 1, 3, and 6 months of storage,
Table 3
Residual Formaldehyde After Second Drying at Ambient Temperature
Residual Formaldehydea (mg/capsule)
Batch After Coating 1 Month 3 Months 6 Months
Colorless 00 0.4280.007 0.1080.007 0.0870.003 0.0800.004
Colorless 0 0.3350.012 0.0830.003 0.0470.002 0.0420.004
Not transparent 0 0.3360.008 0.0650.004 0.0450.004 0.0390.003
aMean values from five experimentsconfidence interval (95%).
Table 4
Disintegration Time in Simulated Intestinal Fluid for Dried Capsules at 37C
Disintegration Timea (min)
Batch After Coating 1 Month 3 Months 6 Months
Colorless 00 9.10.7 8.50.6 8.40.5 8.40.5
Colorless 0 8.50.6 8.70.6 8.70.3 8.80.3
Not transparent 0 8.90.3 8.30.6 8.40.5 8.60.5
aMean values from five experimentsconfidence interval (95%).
Table 5
Disintegration Time in Simulated Intestinal Fluid for Dried Capsules at Ambient Temperature
Disintegration Timea (min)
Batch After Coating 1 Month 3 Months 6 Months
Colorless 00 8.70.3 8.80.9 9.01.0 9.00.8
Colorless 0 8.70.6 8.30.7 8.40.5 8.90.8
Not transparent 0 8.60.5 8.60.5 8.80.3 8.60.5
aMean values from five experimentsconfidence interval (95%).




































Figure 3. Dissolution profile of dried 00 capsules at ambi-
ent temperature.
Figure 4. Dissolution profile of dried colorless 0 capsules
at 37C
Figure 2. Dissolution profile of dried 00 capsules at 37C.
Figure 6. Dissolution profile of dried not transparent 0
capsules at 37C.
Figure 1. Dissolution profile of uncoated capsules.
Figure 5. Dissolution profile of dried colorless 0 capsules
at ambient temperature.




































at 37C and at ambient temperature, we verify a
stabilization of the coating procedure.
CONCLUSIONS
The studied coating allowed us to obtain stable
acetylsalicylic acid gelatin capsules with a good
gastro-resistance and enteros solubility, in accor-
dance with the proposed objectives.
The properties of prepared gelatin capsules are
identical to those obtained by other researchers,
although using a different experimental methodol-
ogy (21,22).
From these results it is possible to affirm that
the application of formaldehyde constitutes a valid
alternative to those methods developed for the enteric
coating of acetylsalicylic acid gelatin capsules.
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